Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226843 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
A Phase 1 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 460
- Enrollment target
NCT07226843 is a Phase 1 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 460 participants.
The verdict
NCT07226843, a Phase 1 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 460 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.
Interventions
- DRUG Rituximab
- DRUG LY4584180
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2026-04-17 |
| Est. Completion | 2030-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07226843
The ClinicalTrials.gov registry entry for NCT07226843 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT07226843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07226843 about?
NCT07226843 is a clinical study titled "A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers". The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer i...
What is the current status of trial NCT07226843?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 460 participants. The study started on 2026-04-17. Estimated completion is 2030-02.
What interventions are being tested in trial NCT07226843?
The interventions under investigation include: Rituximab (DRUG), LY4584180 (DRUG).
Who is sponsoring clinical trial NCT07226843?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.